Lyell Immunopharma Inc (NASDAQ: LYEL) is a clinical-stage cell therapy company focused on developing T-cell-based treatments for cancer. The company generates no product revenue as of the FY2025 10-K (filed 2026-03-12) and funds operations through equity financing while spending on research and development. Lyell's pipeline is centered on ronde-cel and LYL273 as its primary clinical-stage product candidates, with nonclinical research into additional CAR T-cell candidates designed to address T-cell exhaustion, lack of durable stemness, and immune suppression in the tumor microenvironment. The company incurred $158.7 million in research and development expenses during FY2025. Lyell discontinued development of LYL797, LYL845, and LYL119 in 2024 following the acquisition of ronde-cel. Future revenue, if any, is expected from collaborations, licensing agreements, strategic alliances, or eventual product sales. The company holds licensing agreements with UCLA and other academic institutions, carrying milestone and royalty obligations upon commercialization.

Revenue model

No product revenue as of FY2025. The company is pre-commercial and funds operations through equity issuances. Potential future revenue streams cited in the filing include collaborations, strategic alliances, licensing agreements, and product sales. Licensing obligations to UCLA include tiered royalties on net sales in the low-to-mid single digits percentage and milestone payments up to the mid-single digit millions per commercialized product.

Products and services

Primary clinical candidates: ronde-cel (acquired in 2024) and LYL273. Nonclinical research into novel CAR T-cell candidates targeting T-cell exhaustion, stemness durability, and tumor microenvironment immune suppression. Discontinued programs as of 2024: LYL797, LYL845, LYL119.

Customers and end markets

No commercial customers as of FY2025. End market is oncology, specifically patients with cancer treated via cell therapy. Clinical development involves third-party contract research organizations and clinical trial sites.

Value-chain role

Clinical-stage drug developer operating upstream of commercialization. Relies on third-party service providers for clinical research, cloud infrastructure, and manufacturing-related functions. Holds in-licensed IP from UCLA (via ImmPACT acquisition) and Stanford, with success payment obligations to Stanford and royalty and milestone obligations to UCLA upon commercialization.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Allogene Therapeutics Inc Arcus Biosciences Inc Immunitybio Inc Travere Therapeutics Inc Ironwood Pharmaceuticals Inc IVERIC bio, Inc. Krystal Biotech Inc Revolution Medicines Inc Recursion Pharmaceuticals Inc